At Bristol-Myers Squibb we work in partnership with lots of organisations to meet the needs of patients and the NHS. We believe that by working together with patient advocacy groups (PAGs), NHS stakeholders, and healthcare providers we can better deliver innovative pharmaceutical therapies and help people live healthier lives. Bristol-Myers Squibb is committed to working in partnership with others in a way which is fully compliant with the Association of the British Pharmaceutical Industry (ABPI) Code of Practice. Our objective is to act transparently with all stakeholders and the community at large.
For information on transparency disclosure - click here.
The ABPI Code of Conduct
Bristol-Myers Squibb is a member of the Association of the British Pharmaceutical Industry (ABPI) and is committed to operating in a professional, ethical and transparent manner by complying with the ABPI code of practice.
The detailed provisions in the Code aim to ensure that pharmaceutical companies operate in a responsible, ethical and professional manner. It sets standards for the promotion of medicines for prescribing to health professionals and the provision of information to the public about prescription only medicines and covers information made available to the public about prescription medicine. Advertising or promoting prescription only medicines to the public is prohibited under the ABPI Code and UK law.
Date of preparation: May 2015 MLTUK1500052-05